Pharmacokinetics of chlorpromazine and key metabolites
Autor: | Kamal K. Midha, P. K. F. Yeung, John W. Hubbard, E. D. Korchinski |
---|---|
Rok vydání: | 1993 |
Předmět: |
Adult
Male Pharmacology Volume of distribution Chlorpromazine Metabolite Radioimmunoassay Cmax Administration Oral Half-life General Medicine First pass effect chemistry.chemical_compound Bolus (medicine) chemistry Pharmacokinetics Oral administration Injections Intravenous Humans Pharmacology (medical) Biotransformation Half-Life |
Zdroj: | European Journal of Clinical Pharmacology. 45:563-569 |
ISSN: | 1432-1041 0031-6970 |
Popis: | A study was carried out in 11 healthy young men to investigate the pharmacokinetics of chlorpromazine (CPZ) after a bolus intravenous (IV) dose (10 mg) and three single oral doses (25, 50 and 100 mg), with a washout period of two weeks between doses. Plasma levels of CPZ, CPZ N-oxide (CPZNO), CPZ sulfoxide (CPZSO) and both free and conjugated 7-hydroxy-CPZ (7-HOCPZ) were measured by extraction radioimmunoassays. CPZ exhibited multicompartmental pharmacokinetics in most subjects. There was wide between-subject variability in half life (11.05 h), volume of distribution (1215 l), volume of distribution at steady state (642 l) and mean residence time (8.88 h), whereas systemic clearance was somewhat less variable (76.6 l·h−1). All metabolites were present in measurable concentrations in the plasma of 9 of 11 subjects after IV CPZ, whereas free 7-HOCPZ was not detected in the other 2 individuals. With the exception of CPZNO, the biological half lives of the primary metabolites were longer than the half life of CPZ. After oral administration, the percentage of CPZ reaching the systemic circulation intact (F%) was very low (4–38%) and dose dependant. Moreover, both within-subject and between-subject variances were very high. The maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve extrapolated to infinite time (AUC) showed evidence of nonlinearity, whereas half life did not appear to be dose dependant. These data suggest that the high degree of variability in the pharmacokinetics of CPZ is a result of extensive first pass metabolism rather than variation in half life. The mean AUC for the total conjugates of 7-HOCPZ was about two fold higher than that of the parent drug or any other metabolite. This shows that phase II metabolism plays a very significant role in the disposition of CPZ. As a result, the role of CYP2D6 in the 7-hydroxylation of CPZ cannot be fully assessed without taking phase II metabolism into account. |
Databáze: | OpenAIRE |
Externí odkaz: |